BMS pays $650m upfront for Eisai’s first ADC candidate for cancerJapan’s Eisai has hit the jackpot with its first ever antibody-drug conjugate (ADC) drug candidate, attracting a licensing Share XBMS pays $650m upfront for Eisai’s first ADC candidate for cancerhttps://pharmaphorum.com/news/bms-pays-650m-upfront-for-eisais-first-adc-candidate-for-cancer/
